News | Heart Valve Technology | April 06, 2018

University Hospitals Performs Ohio's First Transcatheter Mitral Valve Replacement

New APOLLO trial of Intrepid TMVR system offers alternative option for patients with severe mitral regurgitation

University Hospitals Performs Ohio's First Transcatheter Mitral Valve Replacement

April 6, 2018 —  University Hospitals Harrington Heart & Vascular Institute has officially opened the APOLLO trial, implanting the first Intrepid transcatheter mitral valve replacement system in the study. Alan Markowitz, M.D., and Guilherme F. Attizzani, M.D., performed the procedure, the first in the state of Ohio.

As part of the APOLLO trial, UH patients with severe symptomatic mitral regurgitation will have the opportunity to be randomized to receive either conventional open-heart mitral valve replacement surgery or an investigational transcatheter mitral valve replacement (TMVR). In addition, patients who are not good surgical candidates could have the opportunity of being treated with TMVR.

According to Attizzani, UH interventional cardiologist and co-director, Valve and Structural Heart Disease Center, UH Harrington Heart & Vascular Institute, the APOLLO trial is a welcome development for patients with mitral valve disease.

“There is currently no TMVR technology approved by the FDA [U.S. Food and Drug Administration] and this trial may open a new, very important avenue on the field,” said Attizzani, who is also assistant professor of medicine at Case Western Reserve University School of Medicine. “The only percutaneous technologies we currently have to treat mitral insufficiency are MitraClip, which enables percutaneous native mitral valve repair, and transcatheter valves used for valve-in-valve procedures. This study is, therefore, extremely important as it may lead to a paradigm shift in terms of the treatment of native mitral valve insufficiency.”

The APOLLO trial is testing the Intrepid TMVR system, which is compressed inside a hollow delivery catheter and is inserted between the ribs to enter the heart. The new replacement valve is expanded directly into the malfunctioning mitral valve. The outer stent frame is designed to attach and conform to the native valve without the need for additional sutures, tethers or anchors to secure the prosthesis. The inner stent houses the valve, which is made from bovine tissue and is intended to maintain blood flow.

The Intrepid valve is implanted using a transapical approach through the apex. However, the technology is expected to evolve and become even less invasive.

“Today, surgeons need to open a small hole in the apex of the heart, then the valve is advanced through it and implanted,” said Markowitz, chief surgical officer, and director, Valve and Structural Heart Disease Center, UH Harrington Heart & Vascular Institute, and clinical assistant professor of surgery, CWRU School of Medicine. “It’s a beating-heart procedure without the heart-lung machine. Industry is, however, already working on a technology that is going to be transseptal (i.e., can be done via puncture of the femoral vein). This will further reduce the invasion to the patient by not having to go through the apex.”

UH is the only healthcare system in Northeast Ohio to give its patients access to the APOLLO trial.

“In addition to the APOLLO trial, we offer MitraClip therapy, an FDA-approved therapy for mitral valve insufficiency,” said Markowitz. “We also perform valve-in-valve and other complex procedures. It’s the full spectrum of mitral valve interventions, a combined effort of interventional cardiology and cardiac surgery.”

Once the APOLLO trial is completed, Attizzani expects patients with mitral valve disease to have more options to treat mitral valve disorders.

“Although it is impossible to predict the trial results, my expectation is that the TMVR system will be shown to be safe and effective,” said Attizzani. “If it is demonstrated to be non-inferior to surgical mitral valve replacement, it will be a key step in terms of the potential future approval of this novel technology by the FDA, ultimately enabling more patients to have the option of an effective and less invasive procedure.”

For more information: www.medtronic.com

 

Related Content

The Edwards Lifesciences Sapien 3 TAVR valve. The annual volume of TAVR has increased each year and in 2019 TAVR volume (72,991) exceeded all forms of SAVR (57,626), coinciding with the U.S. Food and Drug Administration (FDA) approval of TAVR for low-risk patients. 

Feature | Heart Valve Technology | November 17, 2020
November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, mor
oston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system. It also initiated a global, voluntary recall of all unused inventory of the Lotus Edge due to complexities associated with the product delivery system. 
Feature | Heart Valve Technology | November 17, 2020 | Dave Fornell, Editor
November 17, 2020 — Boston Scientific Corp.
The Keystone Heart TriGuard 3 (TG3) is a self-stabilizing cerebral embolic deflection filter used in patients undergoing transcatheter aortic valve replacement (TAVR). The device is designed to reduce TAVR complications of cerebral embolization and ischemic stroke. #TCT #TCT2020 #TCTconnect

The Keystone Heart TriGuard 3 (TG3) is a self-stabilizing cerebral embolic deflection filter used in patients undergoing transcatheter aortic valve replacement (TAVR). The device is designed to reduce TAVR complications of cerebral embolization and ischemic stroke. 

News | Heart Valve Technology | October 15, 2020
October 15, 2020 – The REFLECT II randomized clinical trial evaluating the safety and efficacy of the Keystone Heart
The Boston Scientific Acurate neo self-expanding TAVR valve (left) did not perform as well clinically as the Medtronic CoreValve Evolut TAVR valve (right) in the SCOPE II trial presented at TCT 2020. #TCT #TCT2020 #TCTconnect

The Boston Scientific Acurate neo self-expanding TAVR valve (left) did not perform as well clinically as the Medtronic CoreValve Evolut TAVR valve (right) in the SCOPE II trial presented at TCT 2020.

Feature | Heart Valve Technology | October 15, 2020
October 15, 2020 – The SCOPE II trial comparing the Boston Scientific Acurate neo vs.
An illustration showing the MitraClip catheter entering the left atrium through a transseptal puncture. #TCT2020 #TCTconnect

An illustration showing the MitraClip catheter entering the left atrium through a transseptal puncture.

News | Heart Valve Technology | October 15, 2020
October 15, 2020 – The...
Medtronic is starting a randomized, head-to-head study comparing the Medtronic CoreValve Evolut Pro and Pro+TAVR Systems against the balloon-expandable Edwards Sapien 3 and Sapien 3 Ultra Transcatheter Heart Valvestwo transcatheter aortic valve replacement (TAVR) systems in patients with severe symptomatic aortic stenosis (ssAS). 

Medtronic is starting a randomized, head-to-head study comparing the Medtronic CoreValve Evolut Pro and Pro+TAVR Systems against the balloon-expandable Edwards Sapien 3 and Sapien 3 Ultra Transcatheter Heart Valvestwo transcatheter aortic valve replacement (TAVR) systems in patients with severe symptomatic aortic stenosis (ssAS). 

News | Heart Valve Technology | October 14, 2020
October 14, 2020 — Medtronic announced it is starting a randomized, head-to-head study comparing two transcatheter ao
The Cardiac Dimensions Carillon Mitral Contour System, a transcatheter device used to treat functional mitral regurgitation (FMR) in patients with heart failure.
News | Heart Valve Technology | October 02, 2020
October 2, 2020 — Cardiac Dimensions announced the company has closed a $17.5 million Series C financing that will be
Boston Scientific launched the Acurate neo2 transcatheter aortic valve replacement (TAVR) system in Europe. This next-generation transcatheter aortic valve implantation (TAVI) technology is a new platform designed with a number of features to improve upon the clinical performance of the original Acurate neo platform. Compared to the previous generation device, the Acurate neo2 valve system also has an expanded indication for patients with aortic stenosis. #TAVR #TAVI
News | Heart Valve Technology | September 29, 2020
September 29, 2020 — Boston Scientific launched the...